Form 4 · Filed May 26, 2026, 11:33 PM UTC
KALV/KalVista Pharmaceuticals, Inc.
Yea Christopher — CHIEF DEVELOPMENT OFFICER
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
3 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 22, 2026 | S | sell | 2,358 | $27 | $63,158 | 228,759 |
| May 21, 2026 | M | other | 3,750 | — | — | 231,117 |
| May 21, 2026 | M | other | 3,750 | — | — | 41,250 |
Source: SEC EDGAR raw filing ↗ · Accession 0001691102-26-000005